The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients |
| |
Authors: | Akira Horikoshi Kazuhiro Takei Yoshifumi Hosokawa Shigemasa Sawada |
| |
Institution: | (1) Department of Internal Medicine, Nihon University, Nerima-Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-ku, Tokyo 179-0072, Japan |
| |
Abstract: | Twenty-one acute myeloid leukemia (AML) patients were enrolled and received oral induction therapy with cytarabine ocfosfate
(SPAC) and etoposide (EP). The median age was 69 years (range: 33–86). There were 11 patients with de novo AML and 10 AML
cases that had evolved from myelodysplastic syndromes. Seventeen patients had abnormal karyotypes including eight complex
abnormalities, various complications, and 7 of 21 had a poor performance status (PS) with Eastern Cooperative Oncology Group
(ECOG) scores of 3–4. All patients completed induction therapy without severe adverse events. Seven achieved complete remission
(CR), and two achieved partial remission (PR). Uni- and multivariate analyses demonstrated a positive and significant correlation
between the results of therapy (CR ± PR) and overall survival. The plasma concentrations of cytosine arabinoside (ara-C) in
some cases were higher than those previously reported, indicating the accumulation of ara-C with increasing numbers of days
of SPAC administration. We conclude that this therapy is well tolerated and useful for refractory and elderly AML patients. |
| |
Keywords: | Cytarabine ocfosfate Ara-C Etoposide Refractory acute myeloid leukemia Induction therapy |
本文献已被 PubMed SpringerLink 等数据库收录! |
|